Company news
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) news
Every X4 Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
September 9, 2026
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
September 8, 2026
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 6, 2026
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
May 27, 2026
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patient...
April 29, 2026
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 17, 2026
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
March 4, 2026
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 2, 2026
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome
February 27, 2026
X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026
February 3, 2026
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 2, 2026
X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference
November 5, 2025
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 5, 2025
X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for G...
October 27, 2025
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering
October 24, 2025
X4 Pharmaceuticals Announces Proposed Underwritten Public Offering
October 23, 2025
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Developme...
September 29, 2025
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
September 17, 2025
Sitryx appoints Adam Mostafa as Chief Financial Officer
September 8, 2025
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 15, 2025
X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement
August 13, 2025
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
August 12, 2025
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the Eu...
June 16, 2025
X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA
June 10, 2025
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress
May 14, 2025
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
May 1, 2025
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025
April 24, 2025
X4 Pharmaceuticals Announces Reverse Stock Split
April 24, 2025
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 25, 2025
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
March 11, 2025
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in W...
February 19, 2025
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
February 6, 2025
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome
January 24, 2025
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
January 13, 2025
X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting ...
December 4, 2024
X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)
November 13, 2024
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 13, 2024
X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcas...
October 24, 2024
X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
August 8, 2024
X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024
July 30, 2024
X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (C...
June 27, 2024
X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in ...
May 29, 2024
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown fro...
May 9, 2024
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
May 7, 2024
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
April 29, 2024
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
March 21, 2024
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
March 12, 2024
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023
December 9, 2023
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
November 9, 2023